What Is NAD+? Mechanism, Structure, Evidence Tier

What is NAD+? A coenzyme present in every living cell, built and consumed continuously as part of energy metabolism, and not a peptide at all. It is the odd entry in any catalogue of research compounds, because the molecule is neither foreign to the body nor recently discovered. Biochemistry textbooks have described it for decades.

That familiarity is what makes the commercial version difficult to assess. A reader who searches the abbreviation meets a molecule with an enormous scientific literature and reasonably concludes that the vial has that literature behind it. The molecule and the vial are not the same object, and separating them is the only useful work this page can do.

What is NAD+ as a molecule, before anything is sold

Nicotinamide adenine dinucleotide is a dinucleotide: two nucleotide units, one carrying a nicotinamide group and one carrying adenine, joined through their ribose sugars by a pyrophosphate bridge. The plus sign marks the oxidised form, which carries a positive charge on the nicotinamide ring. The reduced partner is written NADH.

The molecule’s primary function is to move a pair of electrons. Enzymes in glycolysis, in the citric acid cycle and in fatty acid oxidation transfer electrons onto NAD+, producing NADH, which carries them to the mitochondrial electron transport chain. NAD+ is then regenerated and the exchange repeats. No cell invents this arrangement; it is one of the most conserved pieces of metabolism there is.

Two jobs, and only one of them consumes the molecule

The electron shuttling described above destroys nothing. The same molecules cycle between the oxidised and reduced states many times.

A second group of enzymes treats NAD+ as a substrate rather than a carrier. Sirtuins, poly ADP ribose polymerases and the ectoenzyme CD38 cleave the molecule and use a fragment, releasing nicotinamide as a product. These reactions consume the pool, so cells continuously rebuild it, mostly by salvaging nicotinamide back into NAD+ through a short enzymatic route rather than by synthesising the molecule from scratch.

That salvage pathway is the reason precursor products exist. Supplying more of a salvage substrate is a plausible way to influence the size of a pool that is constantly turning over, and it is a very different proposition from delivering the finished coenzyme into a vein.

It also explains why the pool is not a static quantity waiting to be topped up. Synthesis and consumption run continuously and are regulated, and the enzymes on both sides respond to conditions inside the cell. Any account of what an administered quantity does has to contend with a system that was already controlling its own supply before the administration happened.

Why a coenzyme appears in a peptide catalogue at all

The grouping is commercial rather than chemical. Suppliers who sell research peptides sell this alongside them because the customer is the same and the regulatory position is similarly ambiguous, not because the molecules have anything in common.

The consequence is that habits of reading carried over from peptide pages misfire here. Purity by mass spectrometry, sequence verification and the question of whether a synthesised chain matches its intended structure are the standard concerns for a peptide vial. For a coenzyme the relevant questions are different: identity and concentration of the compound in solution, sterility and endotoxin content for anything injected, and whether the preparation is stable in the container over the time it sits there. A certificate written for one kind of product does not answer the questions raised by the other.

One abbreviation, three different objects

Almost every accuracy failure on this topic comes from collapsing three things into one name.

The first is the endogenous coenzyme: what your cells already contain and regulate. The second is an oral precursor product, most often nicotinamide riboside or nicotinamide mononucleotide, and also plain nicotinamide or nicotinic acid, all of which the body converts. The third is a preparation of NAD+ itself for injection or intravenous infusion, which is what the abbreviation usually means when it appears on a vendor page.

The scientific literature attaches to these three unevenly, and the imbalance runs in a direction that flatters the third.

What the trial literature is actually about

More than 76,000 records indexed in PubMed mention NAD in some form, and hundreds of registered interventional studies exist. Both facts are true and both are routinely misused, because a search on the abbreviation is not a search on the injectable.

The great majority of those interventional studies test precursors taken by mouth. Where a human result is reported, the intervention was usually nicotinamide riboside or nicotinamide mononucleotide swallowed as a capsule, and the outcome most consistently reported across those trials is a rise in NAD+ concentrations measured in blood. That is a genuine, repeated human finding, and it is a finding about an oral precursor.

It is not a finding about the injected product, and it is not by itself a clinical outcome either. Demonstrating that an intervention moves a biochemical marker in humans establishes that the intervention reaches the system and does something measurable. Whether the marker’s movement produces a change a person would notice or benefit from is a separate question requiring a separate study design.

The remaining categories of NAD research are worth separating too, because a records count sweeps them all together. A large share of those tens of thousands of papers are basic biochemistry: enzyme kinetics, structural work, and studies in which NAD appears as a reagent rather than as an intervention. Another share is observational, measuring concentrations in tissue or blood and correlating them with age or disease state. Neither category tests an administered product in a person at all, in any form.

What the vial leaves undetermined

Sending the intact coenzyme into the bloodstream raises a question the oral route never has to answer. NAD+ is a large, charged molecule, and whether it enters cells intact is not obvious. Extracellular enzymes, including CD38 and the nucleotidases present on cell surfaces, degrade NAD+ outside the cell into smaller fragments, and those fragments are themselves precursors that the salvage pathway can take up.

If that is what predominantly happens, then an infusion is functioning as an expensive precursor delivery system rather than as direct replacement of an intracellular pool, and the mechanistic story printed on vendor pages describes something other than what occurs. This is an open question in the published literature rather than a settled indictment, but the direction it points matters: the distinction between the injected coenzyme and a precursor may be less clean biochemically than the marketing implies, while remaining completely clean at the level of what has actually been tested in people.

Numbers and structures withheld here, and the reason

No molecular weight, formula or concentration figure appears above. Structural values for compounds sold online propagate by copying, and a single transcription error becomes consensus across dozens of pages within a year. Nothing a reader needs in order to evaluate a claim depends on those digits.

What does the evaluating is a shorter list of questions. Which of the three objects does this claim concern. What organism produced the result. Was the intervention swallowed or injected. Was there a comparison group. Can the study be retrieved and read. Applied to most content on this compound, the first two questions alone dispose of the majority of what is asserted.